Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495319 | 0.98 | TSHR (0.49) | TSHRADRA1DADRA1AADRA1BGSK3B | |
| SCHEMBL668453 | 0.95 | TSHR (0.56) | TSHRADRA1DADRA1AADRA1BGSK3B | |
| SCHEMBL9821162 | 0.93 | TSHR (0.44) | TSHRADRA1DADRA1AADRA1BGSK3B | |
| SCHEMBL9821321 | 0.89 | TSHR (0.50) | TSHRADRA1DADRA1AADRA1BGSK3B | |
| SCHEMBL3939476 | 0.89 | TSHR (0.46) | TSHRADRA1DADRA1AADRA1BGSK3B | |
| SCHEMBL9708708 | 0.88 | GSK3A (0.49) | TSHRGSK3BGSK3ALMNAALDH1A1 | |
| SCHEMBL3936078 | 0.84 | TSHR (0.51) | TSHRADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL11512914 | 0.83 | GAA (0.43) | TSHRADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL5158837 | 0.83 | TSHR (0.53) | TSHRADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL11284225 | 0.83 | ALDH1A1 (0.46) | TSHRLMNAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6841682-B2 | Heterocycles useful in the treatment of benign prostatic hyperplasia | JANSEEN PHARMACEUTICA N.V. (BE) | 2005-01-11 | — | — | US | disclosed |
| EP-1273572-B1 | Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia | ORTHO MCNEIL PHARM INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1273572-A1 | Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020165219-A1 | Novel heterocycles useful in the treatment of benign prostatic hyperplasia | HUTCHINGS RICHARD H (US) | 2002-11-07 | — | — | US | disclosed |
| US-20020082421-A1 | Novel solid salt forms of N-[2-[4-[2-(1- methylethoxy)phenyl]-1-piperazinyl]-2-oxo-1piperidineacetamide | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6384035-B1 | TREATING A DISEASE MEDIATED BY THE .ALPHA.-1.SUB.A ADRENERGIC RECEPTOR COMPRISING ADMINISTERING A COMPOUND | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-05-07 | — | — | US | disclosed |
| WO-2002022582-A2 | SOLID SALT FORMS OF N-[2-[4-[2-(1-METHYLETHOXY)PHENYL]-1-PIPERAZINYL]ETHYL]-2-OXO-1-PIPERIDINEACETAMIDE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-1025085-A1 | HETEROCYCLES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND INTERMEDIATES THEREOF | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999019299-A1 | HETEROCYCLES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND INTERMEDIATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| US-4080192-A | POSTEMERGENCE AND PREEMERGENCE HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082421-A1 | Novel solid salt forms of N-[2-[4-[2-(1- methylethoxy)phenyl]-1-piperazinyl]-2-oxo-1piperidineacetamide | NPPA, SCN2A, SLC28A2 | TSHR 4450/4885ADRA1D 1058/4885ADRA1A 1124/4885 |
| US-20020165219-A1 | Novel heterocycles useful in the treatment of benign prostatic hyperplasia | ADRA1A, ADRB1, ADRA1D | TSHR 667/4885ADRA1D 3/4885ADRA1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.